VEGFA and neoplasm: To the best of our knowledge, the present study is the first to demonstrate that 23-demethyl 8,13-deoxynargenicin, termed compound 9, exhibits potential antiangiogenic activity through its inhibitory effects on VEGF/VEGFR2 signaling in ECs and the HIF-1α/VEGF pathway in tumor cells.